1-20 of 107
Jun Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 102: Transient chromosomal instability as a driver of ovarian cancer genome evolution

Ignacio Vazquez-Garcia, Florian Uhlitz, Marc J. Williams, Jun Li, Hongyu Shi, Samuel Freeman, Matthew Myers, MSK SPECTRUM Consortium, Britta Weigelt, Dmitriy Zamarin, Andrew McPherson, Samuel F. Bakhoum, Sohrab P. Shah
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 102.
https://doi.org/10.1158/1538-7445.AM2023-102
Published: 29 May 2023
View article titled, Abstract 102: Transient chromosomal instability as a driver of ovarian cancer genome evolution
Journal Articles

The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer

Jia Liu, Ze-Xian Liu, Jia-Jun Li, Zhao-Lei Zeng, Jin-Hong Wang, Xiao-Jing Luo, Chau-Wei Wong, Jia-Bo Zheng, Heng-Ying Pu, Hai-Yu Mo, Hui Sheng, Qi-Nian Wu, Hao Li, Gang Wan, Bo Li, De-shen Wang, Rui-Hua Xu, Huai-Qiang Ju
Journal: Cancer Research
Cancer Res (2023) 83 (9): 1476–1489.
https://doi.org/10.1158/0008-5472.CAN-22-1922
Published: 02 May 2023
View article titled, The Macrophage-Associated LncRNA <em>MALR</em> Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer
Open the PDF for The Macrophage-Associated LncRNA <em>MALR</em> Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract 5981: TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development

Shengli Dong, Apeng Liang, Jian Zhu, Huan Wang, Meihua Li, Kai Wang, Rongzhen Ni, Haoyun Li, Yundi Cao, Linglin Xiao, Hongqiang Li, Yian Tu, Chao Zhou, Aishen Gong, Shuyi Xu, Hui Su, Chengshan Niu, Mingyu Jiang, Feng Xing, Xiugui Chen, Shaoqing Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5981.
https://doi.org/10.1158/1538-7445.AM2023-5981
Published: 04 April 2023
View article titled, Abstract 5981: TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development
Journal Articles

Abstract 5979: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition

Meihua Li, Chengshan Niu, Mingtao Chen, Kaige Ji, Hui Xu, Shengli Dong, Yan Zhang, Qinguo Meng, Yuge Dou, Yijun Wang, Rui Wu, Yian Tu, Chao Zhou, Apeng Liang, Huan Wang, Rongzhen Ni, Aishen Gong, Hui Su, Mingyu Jiang, Feng Xing, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5979.
https://doi.org/10.1158/1538-7445.AM2023-5979
Published: 04 April 2023
View article titled, Abstract 5979: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
Journal Articles

Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo

Apeng Liang, Shengli Dong, Guangbin Liu, Zhengfei Guo, Meihua Li, Shuaibo Han, Yundi Cao, Yian Tu, Chao Zhou, Yu Yu, Linglin Xiao, Wei Huang, Xinlong Yang, Lian Fang, Haoyun Li, Chengshan Niu, Mingyu Jiang, Feng Xing, Shaoqing Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4491.
https://doi.org/10.1158/1538-7445.AM2023-4491
Published: 04 April 2023
View article titled, Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <em>in vitro</em> and <em>in vivo</em>
Journal Articles

Abstract 4488: TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations

Jun Li, Chengshan Niu, Zhongwei Guo, Huan Wang, Bailu Zheng, Yuge Dou, Apeng Liang, Kaige Ji, Shengli Dong, Meihua Li, Yanchao Zhao, Yazhen Zhang, Aishen Gong, Hao Liu, Xinmiao Hu, Hui Su, Mingyu Jiang, Shaoqing Chen, Xiugui Chen, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4488.
https://doi.org/10.1158/1538-7445.AM2023-4488
Published: 04 April 2023
View article titled, Abstract 4488: TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations
Journal Articles

Abstract 3419: TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models

Chengshan Niu, Maolin Zheng, Huan Wang, Kaige Ji, Meihua Li, Guohui Wang, Rongzhen Ni, Apeng Liang, Aishen Gong, Yazhen Zhang, Hui Su, Mingyu Jiang, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3419.
https://doi.org/10.1158/1538-7445.AM2023-3419
Published: 04 April 2023
View article titled, Abstract 3419: TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models
Journal Articles

Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy

Yanfei Han, Chengzhang Shang, Zhuon li, Zhenyan Han, Jun Li, Zixu Cui, Gao An, Wanjun Hao, Yujie Liu, Hao Li, Baihong Liu, Ellen Zhang, Qingcong Lin, Yi Yang, Yuelei Shen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2978.
https://doi.org/10.1158/1538-7445.AM2023-2978
Published: 04 April 2023
View article titled, Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy
Journal Articles

Abstract 5580: Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial

Yu Wang, Jun Li, Jonathan Baden, Saurabh Gupta, Justin M. David
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5580.
https://doi.org/10.1158/1538-7445.AM2023-5580
Published: 04 April 2023
View article titled, Abstract 5580: Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial
Journal Articles

Abstract 1651: Discovery of oridonin-based proteolysis targeting chimera (PROTAC) compounds as putative protein degraders and potent anticancer agents for triple-negative breast cancer

Ruixia Ma, Jun Li, Gabrielle R. Vontz, Pingyuan Wang, Haiying Chen, Jia Zhou, Qiang Shen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1651.
https://doi.org/10.1158/1538-7445.AM2023-1651
Published: 04 April 2023
View article titled, Abstract 1651: Discovery of oridonin-based proteolysis targeting chimera (PROTAC) compounds as putative protein degraders and potent anticancer agents for triple-negative breast cancer
Journal Articles

Abstract 1659: Development of HJC0152, its analogs and protein degraders to modulate STAT3 for triple-negative breast cancer therapy

Gabrielle Vontz, Jun Li, Ruixia Ma, Jimin Xu, Mingxiang Zhou, Haiying Chen, Jia Zhou, Qiang Shen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1659.
https://doi.org/10.1158/1538-7445.AM2023-1659
Published: 04 April 2023
View article titled, Abstract 1659: Development of HJC0152, its analogs and protein degraders to modulate STAT3 for triple-negative breast cancer therapy
Journal Articles

Abstract 3400: TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations

Chengshan Niu, Apeng Liang, Yuge Dou, Kaige Ji, Meihua Li, Yanchao Zhao, Yan Zhang, Zhongwei Guo, Aishen Gong, Mingyu Jiang, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3400.
https://doi.org/10.1158/1538-7445.AM2023-3400
Published: 04 April 2023
View article titled, Abstract 3400: TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations
Journal Articles

Abstract IA014: Synthetic essentiality identifies TDO2 as a key target in APC-deficient CRC

Rumi Lee, Jiexi Li, Jun Li, Chang-Jiun Wu, Shan Jiang, Wen-Hao Hsu, Deepavali Chakravarti, Peiwen Chen, Kyle A. LaBella, Jing Li, Denise J. Spring, Di Zhao, Y. Alan Wang, Ronald A. DePinho
Journal: Cancer Research
Cancer Res (2022) 82 (23_Supplement_1): IA014.
https://doi.org/10.1158/1538-7445.CRC22-IA014
Published: 01 December 2022
View article titled, Abstract IA014: Synthetic essentiality identifies TDO2 as a key target in APC-deficient CRC
Journal Articles

Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3

Long Liao, Yan He, Shu-Jun Li, Guo-Geng Zhang, Wei Yu, Jing Yang, Zi-Jia Huang, Can-Can Zheng, Qing-Yu He, Yan Li, Bin Li
Journal: Cancer Research
Cancer Res (2022) 82 (13): 2444–2457.
https://doi.org/10.1158/0008-5472.CAN-21-4124
Published: 05 July 2022
View article titled, Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m<sup>6</sup>A Methyltransferase METTL3
Open the PDF for Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m<sup>6</sup>A Methyltransferase METTL3 in another window
Includes: Supplementary data
Journal Articles

Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy

Chengzhang Shang, Liu Yang, Jiyong Zhang, Yanfei Han, Zhuolin Li, Zhenyan Han, Jun Li, Ying Meng, Gao An, Hao Yang, Wenqian An, Lei Chen, John Charpentier
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4256.
https://doi.org/10.1158/1538-7445.AM2022-4256
Published: 15 June 2022
View article titled, Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy
Journal Articles

Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study

Jun Liu, Guangbing Li, Qiang He, Shijun Sun, Chuanlin Zhao, Chuandong Sun, Bo Zhang, Yi Cui, Yongqiang Ye, Xuting Zhi, Shiping Li, Shiping Li, Guozheng Pan, Changlin Ma, Jinhua Hu, Jun Li, Suling Wang, Yuangang Qiao, Wanhua Ren, Qi Meng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5249.
https://doi.org/10.1158/1538-7445.AM2022-5249
Published: 15 June 2022
View article titled, Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study
Journal Articles

Abstract 3822: Chromosomal instability shapes the tumor microenvironment through a chronic ER-stress response

Jun Li, Melissa Hubisz, Ethan Earlie, Mercedes A. Duran, Emanuele Lettera, Su M. Phyu, Amit D. Amin, Matthew Deyell, Erina Kamiya, Karolina Budre, Julie-Ann Cavallo, Christopher Garris, Hannah Wen, Benjamin Izar, Eileen Parkes, Ashley Laughney, Samuel Bakhoum
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3822.
https://doi.org/10.1158/1538-7445.AM2022-3822
Published: 15 June 2022
View article titled, Abstract 3822: Chromosomal instability shapes the tumor microenvironment through a chronic ER-stress response
Journal Articles

Abstract 1330: Role of ENPP1 mediated extracellular cGAMP hydrolysis in cancer metastasis and immune evasion

John Young Ho Kwon, Jun Li, Mercedes Duran, Ninjit Dhanota, Samuel Bakhoum
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1330.
https://doi.org/10.1158/1538-7445.AM2022-1330
Published: 15 June 2022
View article titled, Abstract 1330: Role of ENPP1 mediated extracellular cGAMP hydrolysis in cancer metastasis and immune evasion
Journal Articles

Abstract LB101: Novel Drug-responsive domain (DRD)-based regulation technology enables tightly controlled activity of potent membrane-bound IL12 in adoptive cell therapies

Sean Gregory Smith, James A. Storer, Dexue Sun, Dan Jun Li, Benjamin Primack, Theresa Ross, Scott LaJoie, Jeremy Tchaicha, Dhruv Sethi, Jan ter Meulen, Michelle Ols
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB101.
https://doi.org/10.1158/1538-7445.AM2022-LB101
Published: 15 June 2022
View article titled, Abstract LB101: Novel Drug-responsive domain (DRD)-based regulation technology enables tightly controlled activity of potent membrane-bound IL12 in adoptive cell therapies
Journal Articles

Abstract 5402: Urothelial carcinomas in different anatomical positions exhibit distinct genomic and immunological characteristics

Ruiqian Li, Hushan Zhang, Qilin Wang, Hong Yang, Yu Bai, Chen Hu, Hongyi Wu, Chongjian Zhang, Ziyong Wang, Qiwei Wang, Pengjie Xu, Jun Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5402.
https://doi.org/10.1158/1538-7445.AM2022-5402
Published: 15 June 2022
View article titled, Abstract 5402: Urothelial carcinomas in different anatomical positions exhibit distinct genomic and immunological characteristics